<https://helda.helsinki.fi>

Novel anti-invasive properties of a Fascin1 inhibitor on colorectal cancer cells

Montoro-Garcia, Silvia

2020-03

Montoro-Garcia , S , Albuquerque-Gonzalez , B , Bernabe-Garcia , A , Bernabe-Garcia , M , Rodrigues , P C , den-Haan , H , Luque , I , Jose Nicolas , F , Perez-Sanchez , H , Luisa Cayuela , M , Salo , T & Conesa-Zamora , P 2020 , ' Novel anti-invasive properties of a Fascin1 inhibitor on colorectal cancer cells ' , Journal of Molecular Medicine , vol. 98 , no. 3 , pp. 383-394 . <https://doi.org/10.1007/s00109-020-01877-z>

<http://hdl.handle.net/10138/325423>

<https://doi.org/10.1007/s00109-020-01877-z>

acceptedVersion

Downloaded from Helda, University of Helsinki institutional repository.

This is an electronic reprint of the original article.

This reprint may differ from the original in pagination and typographic detail.

Please cite the original version.

Journal of Molecular Medicine

Novel anti-invasive properties of a Fascin1 inhibitor on colorectal cancer cells

--Manuscript Draft--

Manuscript Number:	JMME-D-19-00045R2
Full Title:	Novel anti-invasive properties of a Fascin1 inhibitor on colorectal cancer cells
Article Type:	Original Article
Corresponding Author:	Pablo Conesa-Zamora, Ph.D, Pharm.D Santa Lucia University Hospital Cartagena, Murcia SPAIN
Corresponding Author Secondary Information:	
Corresponding Author's Institution:	Santa Lucia University Hospital
Corresponding Author's Secondary Institution:	
First Author:	Silvia Montoro-Garcia, Ph.D
First Author Secondary Information:	
Order of Authors:	Silvia Montoro-Garcia, Ph.D
	Begoña Alburquerque-González, BSc
	Ángel Bernabé-García, Ph.D
	Manuel Bernabé-García, Ph.D
	Priscila Campioni Rodrigues, Ph.D
	Helena den Haan, Ph.D
	Irene Luque, Ph.D
	Francisco José Nicolas, Ph.D
	Horacio Pérez-Sánchez, Ph.D
	María Luisa Cayuela, Ph.D
	Tuula Salo, Ph.D
	Pablo Conesa-Zamora, Ph.D, Pharm.D
Order of Authors Secondary Information:	
Abstract:	<p>Tumor invasion and metastasis involve processes in which actin cytoskeleton rearrangement induced by Fascin1 plays a crucial role. Indeed, Fascin1 has been found overexpressed in tumors with worse prognosis. Migrastatin and its analogues target Fascin1 and inhibit its activity. However, there is need for novel and smaller Fascin1 inhibitors. The aim of this study was to assess the effect of compound G2 in colorectal cancer cell lines and compare it to migrastatin in <i>in vitro</i> and <i>in vivo</i> assays. Molecular modeling, actin bundling, cell viability, immunofluorescence, migration and invasion assays were carried out in order to test anti-migratory and anti-invasive properties of compound G2. In addition, the <i>in vivo</i> effect of compound G2 was evaluated in a zebrafish model of invasion. HCT-116 cells exhibited the highest Fascin1 expression from eight tested colorectal cancer cell lines. Compound G2 showed important inhibitory effects on actin bundling, filopodia formation, migration and invasion in different cell lines. Moreover, compound G2 treatment resulted in significant reduction of invasion of DLD-1 overexpressing Fascin1 and HCT-116 in zebrafish larvae xenografts; this effect being less evident in Fascin1 known-down HCT-116 cells. This study proves, for the first time, the <i>in vitro</i> and <i>in vivo</i> antitumoral activity of compound G2 on colorectal cancer cells and guides to design improved compound G2-based Fascin1 inhibitors.</p>

Response to Reviewers:**General remarks:**

Careful proofreading is necessary.

REPLY: The manuscript has been now reviewed carefully by a native English speaker. It is required to use the same cell lines for each assay: HCT-116 control + HCT-116 fascin siRNA and DLD1 control + fascin overexpression.

REPLY: We understand the referee's comment and we have now performed the corresponding experiments accordingly. All of them are now included in the new version of the manuscript (main text and supplemental material).

We are now describing to the referee the main issues about the above assays with transfected cells.

Figure 2. This is not new but has been already shown by Huang et al., 2015. The evaluation method to analyze the effect of the compounds on fascin is not clear and it is not possible to read the graph labeling.

REPLY: Huang et al. (2018) performed elegant experiments to identify small molecules that specifically block filopodia formation, cell migration and invasion. Compound G2 was among these molecules. They appropriately used fluorescence microscopy (63x magnification) together with isothermal titration calorimetry to test the biochemical mechanism by which G2 inhibits fascin1. Nonetheless, transmission electronic microscopy (TEM) (135,000x magnification), as we presented here, was not used in the referred paper.

Moreover, we have now modified the graph labelling in Figure 2.

Huang, J., Dey, R., Wang, Y., Jakoncic, J., Kurinov, I., & Huang, X. Y. (2018).

Structural Insights into the Induced-fit Inhibition of Fascin by a Small-Molecule Inhibitor. J Mol Biol, 430(9), 1324-1335. doi:10.1016/j.jmb.2018.03.009

Figure 3: Only HCT-116 cells were analyzed the other cell lines are missing, see "general remarks"

REPLY: Not all cell lines are suitable to assess filopodia formation. In order to provide an extra cell line to demonstrate the effect of compound G2, HaCaT human cells were used. HaCaT are spontaneously immortalized human keratinocyte cells expressing high levels of fascin1 (<https://www.proteinatlas.org/ENSG00000075618-FSCN1/cell>). As it is shown in the following figure (for reviewer only), lamellipodia formation in the presence of compound G2 was clearly abolished in HaCat cells, confirming once more the implication of the drug in the lamellipodia formation.

Figure for review only: Representative images of immunofluorescence assays of HaCat cells for fascin1 (green), nucleus (blue) and actin (red) are shown. A) Control condition (DMSO); B) 10 ng/mL Epidermal Growth Factor (EGF, migration stimulator); C) 50 μ M PD98059 (Mek inhibitor); D) 100 μ M migrastatin; E) 10 μ M compound G2. Cells were fixed with bouin and co-stained with anti-Fascin1 antibody (1/250) and Hoechst-33258. For actin staining, cells were fixed with methanol and stained with anti-actin antibody (1/1000) and Hoechst-33258. Images were captured with a LSM 510 META confocal fluorescence microscope with 63X oil objective.

RESULTS (PAGE 14): "Similar results were observed with an extra cell line expressing Fascin1 (HaCat) as DLD1 morphology was not suitable for assessing lamellipodium formation (data not shown)".

Additionally, we now include the immunofluorescence assay with genetically knocked-down HCT-116 for fascin1 (Supplementary material S5). The resulting experiment shows that lamellipodia formation is clearly compromised in fascin1 silenced cells and therefore, the effect of G2 cannot be exerted in an additive fashion. Nonetheless, it is important to notice that 100% transfection efficiency was not achieved and thus, some cells are stained in green and still display lamellipodia.

When pharmacological inhibition (compound G2) is added to knocked-down cells, lamellipodia are also abolished. The following figure includes the effect of compound G2 on silenced cells. Nonetheless, in the supplementary material we have only added columns A-D because the lamellipodia formation in silenced cells was already abolished without the drug.

Figure for review only: Representative images of immunofluorescence assays for fascin1 (green), nucleus (blue) and actin (red) are shown. A) Control condition (DMSO) with siRNA-A transfected HCT-116 cells; B) Control condition (DMSO) with fascin1 silenced HCT-116 cells; C) Fascin1 silenced HCT-116 cells with 10 ng/mL Epidermal Growth Factor (EGF, migration stimulator), D) Fascin1 silenced HCT-116 cells with 50 μ M PD98059 (Mek inhibitor); E) Fascin1 silenced HCT-116 cells with 20 μ M compound G2. Colorectal carcinoma HCT-116 cells were genetically knocked-down for Fascin1

with short interfering siRNA, control HCT-116 was transfected with siRNA-A (MOCK). Cells were fixed with bouin and co-stained with anti-Fascin1 antibody (1/250) and Hoechst-33258. For actin staining, cells were fixed with methanol and stained with anti-actin antibody (1/1000). Images were captured with a LSM 510 META confocal fluorescence microscope with 63X oil objective.

Figure 4: The siRNA and overexpressing approaches are missing. Figure 5: Only HCT-116 cells were analyzed the other cell lines are missing, see "general remarks"

REPLY: As suggested by the referee, a new supplemental figure (S9) has been included presenting new migration and invasion assays using HCT-116 control + HCT-116 fascin1 siRNA and DLD1 control + fascin1 overexpression. In this way, genetic and pharmacological inhibitions could be analyzed in vitro.

Figure for review only: Scratch of transfected DLD-1 cells with pGFP-Fsc1.

Fascin1 silenced HCT-116 cells lead to a slightly decrease in migration and invasion compared to MOCK HCT-116 cells, being more significant in the presence of compound G2. Similarly, DLD1 overexpressing Fascin1 migrate and invade significantly more than MOCK DLD-1 cells whilst treated DLD1 cells display reduced capacities.

Supplementary material S9. Inhibition of the migration and invasive capacities exerted by compound G2 on transfected cells Colorectal carcinoma HCT-116 cells were genetically knocked-down for Fascin1 with short interfering siRNA, MOCK control HCT-116 was transfected with siRNA-A: A) Percentage of migration. B) Percentage of invasion. Colorectal carcinoma DLD-1 cells were genetically overexpressed for Fascin1 with Fascin1-GFP vector, MOCK control DLD-1 was transfected with pGFP N3 control vector: C) Percentage of migration. D) Percentage of invasion Data are representative of two similar experiments Error bars, mean $\pm$ SD of duplicates. * $p < 0.05$, ** $p < 0.01$ compared to MOCK condition; n.s: non-significant.

Figure 6: "Good correlation was observed between Fascin1 expression and cell invasion". This is not true HCT-15 cells exhibit higher fascin mRNA levels than DLD1 cells and there is not difference between these cell lines.

REPLY: The reviewer's comment is pertinent. This statement can be applied for most but not all cell lines assayed. Therefore, the sentence has been reworded as follows: RESULTS (PAGE 18): "Good correlation was observed between Fascin1 expression and cell invasion for all cell lines assayed except HCT-15 whose invasion was lower than expected possibly due to other fascin1 independent factors affecting invasion (Figure 6B). Therefore, and because of good correlation, HCT-116 was selected for being the cell line with the highest and DLD-1 for its lower Fascin1 expression and cell invasion."

Figure 7: These experiments have been properly done. However, there are still some concerns. Figure 7C. There is no significant (n.s.) difference between siRNA control cells treated with 5 or 10 μ M G2. Why is the dose-dependency missing in Fascin-expressing cells? The same is true for Figure 7F, in fascin expressing cells one would expect a dose-dependency.

REPLY: We understand the reviewer's concerns about the dose-dependency relationship in transfected cells. Migration and invasion are complex processes involving other proteins and factors apart from fascin1. The invasion capacity cannot be only associated with fascin1 levels.

The expression of fascin1 in silenced HCT-116 cells was low and with such low levels, it was difficult to find a clear dose-dependent relationship of an inhibitory compound (although a trend was shown). Nevertheless, the demonstration that the effect of G2 is fascin1 dependent comes from the comparison between siRNA fascin1 HCT-116 and Fascin1 transfected DLD1 (Fig 7C and 7F) where the inhibitory effect of G2 on invasion is maximum when fascin1 is overexpressed and minimum when it is silenced.

Accordingly, this inhibitory effect is intermediate when fascin1 expression is not altered by transfection. It is clear that close concentrations (i.e. 5 and 10 μ M) can result in non-significant relationship although the tendency is visible by comparing the bar heights. Although a significant effect compared to MOCK conditions was found, the absence of this tendency in Fascin1 transfected DLD1 (Fig. 7F) could be explained by the fact that the G2 inhibitory activity is in its maximum (regardless 5 or 10 μ M G2) because under this circumstance, invasion is more dependent on Fascin1 (which is exogenously overexpressed) compared to the non-transfected condition that is closer to the in vivo condition. Nonetheless, there is a common anti-invasive phenotype when either pharmacological or genetic inhibition are performed in HCT-116 cells. Huang et al

	<p>(2018) firstly described this fascin1 inhibitory effect to be specific. Using high-throughput screening, Huang et al. identified and characterized small molecules that inhibit the actin-bundling activity of fascin. Focusing on one G2 and breast cancer cells, they demonstrated that it specifically blocks filopodial formation, migration and invasion in vitro, and metastasis in vivo (Nat Commun. 2015 Jun 17;6:7465). Another proof suggesting a direct effect of G2 on fascin1 was the recently published X-ray structure of G2 binding fascin1 published by the same group (J Mol Biol. 2018 Apr 27;430(9):1324-1335) and cited in the manuscript. Despite these findings including ours we cannot exclude additional off-target effects of G2. For this reason, we have included the following sentence in the discussion.</p> <p>DISCUSSION (PAGE 21): "However and despite these evidences, additional off-target anti-tumoral effects of G2 apart from Fascin1 are also possible".</p> <p>Huang, J., Dey, R., Wang, Y., Jakoncic, J., Kurinov, I., & Huang, X. Y. (2018). Structural Insights into the Induced-fit Inhibition of Fascin by a Small-Molecule Inhibitor. J Mol Biol, 430(9), 1324-1335. doi:10.1016/j.jmb.2018.03.009</p> <p>Huang J, Dey R, Wang Y, Jakoncic J, Kurinov I, Huang XY. Structural Insights into the Induced-fit Inhibition of Fascin by a Small-Molecule Inhibitor. J Mol Biol. 2018 Apr 27;430(9):1324-1335. doi: 10.1016/j.jmb.2018.03.009.</p> <p>Overall important experiments are still missing and often the interpretation of the results is wrong. In addition, the writing of the MS has to be improved.</p> <p>I recommend to only accept the manuscript for publication if all experiments were performed (see above) and, more importantly, when the results were correctly interpreted.</p> <p>REPLY: All important experiments assessing migration and invasion have now been performed using the two cell lines with Fascin1 overexpressed and silenced when appropriate. The evidence reporting now here demonstrated an inhibitory effect of G2 compound on actin bundling and cell migration and invasion, these last effect being more evident in Fascin1 overexpressing than Fascin1 knock-down tumor cells thus suggesting a direct effect of G2 on Fascin1 although additional off-target effects cannot be excluded. An extensive review by a native English speaker has been carried out to improve the manuscript quality and understanding.</p>	
Funding Information:	Instituto de Salud Carlos III (PI12/1232)	Dr. Pablo Conesa-Zamora
	Instituto de Salud Carlos III (PI15/00626)	Dr. Pablo Conesa-Zamora
	Ministerio de Economía, Industria y Competitividad, Gobierno de España (CTQ2017-87974-R)	Dr. Horacio Pérez-Sánchez
	Fundación Séneca (18946/JLI/13)	Dr. Horacio Pérez-Sánchez
	H2020 Marie Skłodowska-Curie Actions (FP7/2007-2013)	Dr Silvia Montoro-Garcia

Reviewers' comments:

General remarks:

Careful proofreading is necessary.

REPLY: The manuscript has been now reviewed carefully by a native English speaker.

It is required to use the same cell lines for each assay: HCT-116 control + HCT-116 fascin siRNA and DLD1 control + fascin overexpression.

REPLY: We understand the referee's comment and we have now performed the corresponding experiments accordingly. All of them are now included in the new version of the manuscript (main text and supplemental material).

We are now describing to the referee the main issues about the above assays with transfected cells.

Figure 2. This is not new but has been already shown by Huang et al., 2015. The evaluation method to analyze the effect of the compounds on fascin is not clear and it is not possible to read the graph labeling.

REPLY: Huang et al. (2018) performed elegant experiments to identify small molecules that specifically block filopodia formation, cell migration and invasion. Compound G2 was among these molecules. They appropriately used fluorescence microscopy (63x magnification) together with isothermal titration calorimetry to test the biochemical mechanism by which G2 inhibits fascin1. **Nonetheless, transmission electronic microscopy (TEM) (135,000x magnification), as we presented here, was not used in the referred paper.**

Moreover, we have now modified the graph labelling in Figure 2.

Huang, J., Dey, R., Wang, Y., Jakoncic, J., Kurinov, I., & Huang, X. Y. (2018). Structural Insights into the Induced-fit Inhibition of Fascin by a Small-Molecule Inhibitor. *J Mol Biol*, 430(9), 1324-1335. doi:10.1016/j.jmb.2018.03.009

Figure 3: Only HCT-116 cells were analyzed the other cell lines are missing, see "general remarks"

REPLY: Not all cell lines are suitable to assess filopodia formation. In order to provide an extra cell line to demonstrate the effect of compound G2, HaCaT human cells were used. HaCaT are spontaneously immortalized human keratinocyte cells expressing high levels of fascin1 (<https://www.proteinatlas.org/ENSG00000075618-FSCN1/cell>). As it is shown in the following figure (for reviewer only), lamellipodia formation in the presence of compound G2 was clearly abolished in HaCat cells, confirming once more the implication of the drug in the lamellipodia formation.

Figure for review only: Representative images of immunofluorescence assays of HaCat cells for fascin1 (green), nucleus (blue) and actin (red) are shown. A) Control condition (DMSO); B) 10 ng/mL Epidermal Growth Factor (EGF, migration stimulator); C) 50 μ M PD98059 (Mek inhibitor); D) 100 μ M migrastatin; E) 10 μ M compound G2. Cells were fixed with bouin and co-stained with anti-Fascin1 antibody (1/250) and Hoechst-33258. For actin staining, cells were fixed with methanol and stained with anti-actin antibody (1/1000) and Hoechst-33258. Images were captured with a LSM 510 META confocal fluorescence microscope with 63X oil objective.

RESULTS (PAGE 14): “Similar results were observed with an extra cell line expressing Fascin1 (HaCat) as DLD1 morphology was not suitable for assessing lamellipodium formation (data not shown)”.

Additionally, we now include the immunofluorescence assay with genetically knocked-down HCT-116 for fascin1 (Supplementary material S5). **The resulting experiment shows that lamellipodia formation is clearly compromised in fascin1 silenced cells and therefore, the effect of G2 cannot be exerted in an additive fashion.** Nonetheless, it is important to notice that 100% transfection efficiency was not achieved and thus, some cells are stained in green and still display lamellipodia.

When pharmacological inhibition (compound G2) is added to knocked-down cells, lamellipodia are also abolished. The following figure includes the effect of compound G2 on silenced cells. Nonetheless, in the supplementary material we have only added columns A-D because the lamellipodia formation in silenced cells was already abolished without the drug.

Figure for review only: Representative images of immunofluorescence assays for fascin1 (green), nucleus (blue) and actin (red) are shown. A) Control condition (DMSO) with siRNA-A transfected HCT-116 cells; B) Control condition (DMSO) with fascin1 silenced HCT-116 cells; C) Fascin1 silenced HCT-116 cells with 10 ng/mL Epidermal Growth Factor (EGF, migration stimulator), D) Fascin1 silenced HCT-116 cells with 50 μ M PD98059 (Mek inhibitor); E) Fascin1 silenced HCT-116 cells with 20 μ M compound G2. Colorectal carcinoma HCT-116 cells were genetically knocked-down for Fascin1 with short interfering siRNA, control HCT-116 was transfected with siRNA-A (MOCK). Cells were fixed with bouin and co-stained with anti-Fascin1 antibody (1/250) and Hoechst-33258. For actin staining, cells were fixed with methanol and stained with anti-actin antibody (1/1000). Images were captured with a LSM 510 META confocal fluorescence microscope with 63X oil objective.

Figure 4: The siRNA and overexpressing approaches are missing. Figure 5: Only HCT-116 cells were analyzed the other cell lines are missing, see "general remarks"

REPLY: As suggested by the referee, a new supplemental figure (S9) has been included presenting new migration and invasion assays using HCT-116 control + HCT-116 fascin1 siRNA and DLD1 control + fascin1 overexpression. In this way, genetic and pharmacological inhibitions could be analyzed *in vitro*.

Figure for review only: Scratch of transfected DLD-1 cells with pGFP-Fsc1.

Fascin1 silenced HCT-116 cells lead to a slightly decrease in migration and invasion compared to MOCK HCT-116 cells, being more significant in the presence of compound G2. Similarly, DLD1 overexpressing Fascin1 migrate and invade significantly more than MOCK DLD-1 cells whilst treated DLD1 cells display reduced capacities.

Supplementary material S9. Inhibition of the migration and invasive capacities exerted by compound G2 on transfected cells Colorectal carcinoma HCT-116 cells were genetically knocked-down for Fascin1 with short interfering siRNA, MOCK control HCT-116 was transfected with siRNA-A: A) Percentage of migration. B) Percentage of invasion. Colorectal carcinoma DLD-1 cells were genetically overexpressed for Fascin1 with Fascin1-GFP vector, MOCK control DLD-1 was transfected with pGFP N3 control vector: C) Percentage of migration. D) Percentage of invasion Data are representative of two similar experiments Error bars, mean $\pm$ SD of duplicates. * $p < 0.05$, ** $p < 0.01$ compared to MOCK condition; n.s: non-significant.

Figure 6: "Good correlation was observed between Fascin1 expression and cell invasion". This is not true HCT-15 cells exhibit higher fascin mRNA levels than DLD1 cells and there is not difference between these cell lines.

REPLY: The reviewer's comment is pertinent. This statement can be applied for most but not all cell lines assayed. Therefore, the sentence has been reworded as follows:

RESULTS (PAGE 18): "Good correlation was observed between Fascin1 expression and cell invasion for all cell lines assayed except HCT-15 whose invasion was lower than expected possibly due to other fascin1 independent factors affecting invasion (Figure 6B). Therefore, and because of good correlation, HCT-116 was selected for being the cell line with the highest and DLD-1 for its lower Fascin1 expression and cell invasion."

Figure 7: These experiments have been properly done. However, there are still some concerns. Figure 7C. There is no significant (n.s.) difference between siRNA control cells treated with 5 or 10 μ M G2. Why is the dose-dependency missing in Fascin-expressing cells? The same is true for Figure 7F, in fascin expressing cells one would expect a dose-dependency.

REPLY: We understand the reviewer's concerns about the dose-dependency relationship in transfected cells. Migration and invasion are complex processes involving other proteins and factors apart from fascin1. The invasion capacity cannot be only associated with fascin1 levels.

The expression of fascin1 in silenced HCT-116 cells was low and with such low levels, it was difficult to find a clear dose-dependent relationship of an inhibitory compound (although a trend was shown). Nevertheless, the demonstration that the effect of G2 is fascin1 dependent comes from the comparison between siRNA fascin1 HCT-116 and Fascin1 transfected DLD1 (Fig 7C and 7F) where the inhibitory effect of G2 on invasion is maximum when fascin1 is overexpressed and minimum when it is silenced. Accordingly, this inhibitory effect is intermediate when fascin1 expression is not altered by transfection. It is clear that close concentrations (i.e. 5 and 10 μ M) can result in non-significant relationship although the tendency is visible by comparing the bar heights. Although a significant effect compared to MOCK conditions was found, the absence of this tendency in Fascin1 transfected DLD1 (Fig. 7F) could be explained by the fact that the G2 inhibitory activity is in its maximum (regardless 5 or 10 μ M G2) because under this circumstance, invasion is more dependent on Fascin1 (which is exogenously overexpressed) compared to the non-transfected condition that is closer to the in vivo condition. Nonetheless, there is a common anti-invasive phenotype when either pharmacological or genetic inhibition are performed in HCT-116 cells. Huang et al (2018) firstly described this fascin1 inhibitory effect to be specific.

Using high-throughput screening, Huang et al. identified and characterized small molecules that inhibit the actin-bundling activity of fascin. Focusing on one G2 and breast cancer cells, they demonstrated that it specifically blocks filopodial formation, migration and invasion in vitro, and metastasis in vivo (Nat Commun. 2015 Jun 17;6:7465). Another proof suggesting a direct effect of G2 on fascin1 was the recently published X-ray structure of G2 binding fascin1 published by the same group (J Mol Biol. 2018 Apr 27;430(9):1324-1335) and cited in the manuscript. Despite these findings including ours we cannot exclude additional off-target effects of G2. For this reason, we have included the following sentence in the discussion.

DISCUSSION (PAGE 21): "However and despite these evidences, additional off-target anti-tumoral effects of G2 apart from Fascin1 are also possible".

Huang, J., Dey, R., Wang, Y., Jakoncic, J., Kurinov, I., & Huang, X. Y. (2018). Structural Insights into the Induced-fit Inhibition of Fascin by a Small-Molecule Inhibitor. *J Mol Biol*, 430(9), 1324-1335. doi:10.1016/j.jmb.2018.03.009

Huang J, Dey R, Wang Y, Jakoncic J, Kurinov I, Huang XY. Structural Insights into the Induced-fit Inhibition of Fascin by a Small-Molecule Inhibitor. *J Mol Biol*. 2018 Apr 27;430(9):1324-1335. doi: 10.1016/j.jmb.2018.03.009.

Overall important experiments are still missing and often the interpretation of the results is wrong. In addition, the writing of the MS has to be improved.

I recommend to only accept the manuscript for publication if all experiments were performed (see above) and, more importantly, when the results were correctly interpreted.

REPLY: All important experiments assessing migration and invasion have now been performed using the two cell lines with Fascin1 overexpressed and silenced when appropriate. The evidence reporting now here demonstrated an inhibitory effect of G2 compound on actin bundling and cell migration and invasion, these last effect being more evident in Fascin1 overexpressing than Fascin1 knock-down tumor cells thus suggesting a direct effect of G2 on Fascin1 although additional off-target effects cannot be excluded. An extensive review by a native English speaker has been carried out to improve the manuscript quality and understanding.

Cartagena, December the 5th 2019

Dear Editor,

Please find enclosed the revised version of our work: **"Novel anti-migratory and anti-invasive properties of a Fascin1 inhibitor on colorectal cancer cells"**

In the current version of the manuscript, we have given point-by-point response to all reviewer's questions for which we have performed new assays requested by the reviewer in his second revision. These new experiments includes, when appropriate, silencing and overexpression of fascin1 in HCT-116 and DLD1 cell lines, respectively in order to assess the effect of G2 compound on migration and invasion of tumor cells both *in vitro* and *in vivo*. Besides, we show that G2 disrupts the fascin-actin filament interactions (transmission electron microscopy) and cellular lamellipodia formation (confocal microscopy) in colorectal cancer cells. Text changes from the first revision are highlighted in yellow and from the second revision in light blue.

During more than eight years our group have been characterizing the molecular features of serrated pathway of the colorectum and found out that Fascin1 was an interesting molecular target. This study reports for the first time that a Fascin1 inhibitor has anti-migratory and anti-invasive properties in colorectal cancer cells even at lower concentrations than migrastatin, one the most characterized Fascin1 inhibitor. Using this strategy, we have here confirmed a novel class of compounds that can be a foundation for treating cancer characterized by fascin1 overexpression such as Serrated Adenocarcinoma of the colorectum. The study provides significant evidence that G2 compound is an interesting candidate for further investigation/chemical modifications to develop new Fascin1-specific therapies for colorectal cancer and constitutes the first rationale for a tailored therapy in serrated adenocarcinoma.

Hospital General Universitario
Santa Lucía
C/ Mezquita s/n, Paraje los Arcos
Barrio de Santa Lucía, 30202 - Cartagena - Murcia

All authors have contributed to and agreed on the content of the manuscript, and the respective roles of each author. The manuscript is original and has not been published previously, in any language, in whole or in part, and is not currently under consideration elsewhere. The study was approved by the Hospital Ethics Committee and was carried out in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments.

Your comments and suggestions will be greatly appreciated.

Yours faithfully.

Pablo Conesa Zamora, PharmD.

Key messages

- Fascin is crucial for tumor invasion and metastasis and is overexpressed in bad prognostic tumors
- Several adverse tumors overexpress Fascin1 and lack targeted therapy
- Anti-fascin G2 is for the first time evaluated in colorectal carcinoma and compared with migrastatin
- Filopodia formation, migration activity and invasion *in vitro* and *in vivo* assays were performed
- G2 blocks actin structures, migration and invasion of colorectal cancer cells as fascin dependent

Novel anti-invasive properties of a Fascin1 inhibitor on colorectal cancer cells

Silvia Montoro-García^{a*}, Begoña Albuquerque-González^{b*}, Ángel Bernabé-García^c,
Manuel Bernabé-García^d, Priscila Campioni Rodrigues^e, Helena den-Haan^f, Irene
Luque^g, Francisco José Nicolas^c, Horacio Pérez-Sánchez^h, María Luisa Cayuela^d, Tuula
Salo^{e,i}, Pablo Conesa-Zamora^{b,j}

*Equally contributed

a. Cátedra de Riesgo Cardiovascular, Facultad de Ciencias de la Salud, UCAM
Universidad Católica San Antonio de Murcia, Campus de los Jerónimos, s/n, Guadalupe
30107 Murcia, Spain.

b. Pathology and Histology Department Facultad de Ciencias de la Salud, UCAM
Universidad Católica San Antonio de Murcia, Campus de los Jerónimos, s/n, Guadalupe
30107 Murcia, Spain.

c. Laboratorio de Regeneración, Oncología Molecular y TGF- β . Biomedical Research
Institute of Murcia (IMIB-Arrixaca), Carretera Madrid-Cartagena. El Palmar, Murcia,
Spain.

d. Telomerase, Cancer and Aging Group, University Clinical Hospital “Virgen de la
Arrixaca”, Biomedical Research Institute of Murcia (IMIB-Arrixaca) Murcia, Spain.

e. Cancer and Translational Medicine Research Unit, Faculty of Medicine, University of
Oulu, Aapistie 5A, FI-90220, Oulu, Finland and Medical Research Center Oulu, Oulu
University Hospital, University of Oulu, Oulu, Finland.
Priscila.CampioniRodrigues@oulu.fi

1 f. Eurofins Villapharma Research, Parque Tecnológico de Fuente Álamo. Ctra. El
2 Estrecho-Lobosillo, Km 2,5. Av. Azul E, 30320, Murcia, Spain.
3

4
5 g. Department of Physical Chemistry and Institute of Biotechnology, University of
6 Granada, Campus Fuentenueva s/n 18071 Granada, Spain.
7

8
9 h. Structural Bioinformatics and High Performance Computing (BIO-HPC) Research
10 Group, Universidad Católica de Murcia (UCAM), Guadalupe, Spain.
11

12
13 i. Institute of Oral and Maxillofacial Disease, University of Helsinki, and HUSLAB,
14 Department of Pathology, Helsinki University Hospital, Helsinki, Finland.
15

16
17 j. Clinical Analysis Department, Group of Molecular Pathology and Pharmacogenetics,
18 Biomedical Research Institute from Murcia (IMIB), Hospital Universitario Santa Lucía,
19 c/Mezquita sn, 30202 Cartagena, Spain.
20
21

22
23
24
25
26
27
28
29
30
31
32
33
34 Corresponding authors:
35

36
37 Silvia Montoro-Garcia. Campus de los Jerónimos, s/n, Guadalupe 30107 Murcia, Spain.
38
39 Tel: +34 968278655. Email: smontoro@ucam.edu. Orcid: orcid.org/0000-0002-1948-1022
40
41
42
43
44

45
46 Pablo Conesa-Zamora. c/Mezquita sn, 30202 Cartagena, Spain. Tel +34 968128602 Ext
47
48 951615. Email: pablo.conesa@carm.es. [Orcid: orcid.org/0000-0003-0190-3044](https://orcid.org/0000-0003-0190-3044)
49
50

51 52 53 54 55 **Conflict of interest statement** 56

57
58 The authors confirm that there are no conflicts of interest.
59
60
61
62
63
64
65

Acknowledgments

This project received grants from Instituto de Salud Carlos III (Spanish Ministry of Health) and FEDER funds (ref: PI12/1232 and PI15/00626), Spanish Ministry of Economy and Competitiveness MINECO (CTQ2017-87974-R), and by the Fundación Séneca del Centro de Coordinación de la Investigación de la Región de Murcia under Projects 18946/JLI/13 and 20646/JLI/18. BAG belongs to the “Programa de Doctorado en Ciencias de la Salud, Universidad Católica de Murcia (UCAM)” and holds a grant of the UCAM. PCR was supported by Finnish Cultural Foundation Grant (2017-2018).

This research was partially supported by the e-infrastructure program of the Research Council of Norway, and the supercomputer center of UiT - the Arctic University of Norway, and by the supercomputing infrastructure of Poznan Supercomputing Center.

Abstract

Tumor invasion and metastasis involve processes in which actin cytoskeleton rearrangement induced by Fascin1 plays a crucial role. Indeed, Fascin1 has been found overexpressed in tumors with worse prognosis. Migrastatin and its analogues target Fascin1 and inhibit its activity. However, there is need for novel and smaller Fascin1 inhibitors. The aim of this study was to assess the effect of compound G2 in colorectal cancer cell lines and compare it to migrastatin in *in vitro* and *in vivo* assays. Molecular modeling, actin bundling, cell viability, immunofluorescence, migration and invasion assays were carried out in order to test anti-migratory and anti-invasive properties of compound G2. In addition, the *in vivo* effect of compound G2 was evaluated in a zebrafish model of invasion. HCT-116 cells exhibited the highest Fascin1 expression from eight tested colorectal cancer cell lines. Compound G2 showed important inhibitory effects on actin bundling, filopodia formation, migration and invasion in different cell lines. Moreover, compound G2 treatment resulted in significant reduction of invasion of DLD-1 overexpressing Fascin1 and HCT-116 in zebrafish larvae xenografts; this effect being less evident in Fascin1 known-down HCT-116 cells. This study proves, for the first time, the *in vitro* and *in vivo* antitumoral activity of compound G2 on colorectal cancer cells and guides to design improved compound G2-based Fascin1 inhibitors.

Keywords: Fascin1; Migrastatin; Invasion; Migration; Zebrafish xenograft; Colorectal Cancer.

Introduction

Tumor metastasis remains the leading cause of cancer mortality (Chen, Yang, Jakoncic, Zhang, & Huang, 2010). Acquisition of invading capacity is a prerequisite for carcinoma cells to get access to vessels and thus spread throughout the body. This process involves actin cytoskeleton rearrangement allowing the tumor cells to develop cellular protrusions, such as filopodia and lamellipodium, which contribute to cancer cell migration, invasion, and metastasis (Machesky & Li, 2010). Fascin1 (FSCN1: ENSG00000075618) is a key protein in membrane protrusion, as it possesses actin-binding and actin-bundling activity by cross-linking filamentous actin into tightly packed parallel bundles. Fascin1 expression is often elevated in malignant tumors while its expression is low or absent in most normal adult epithelia (Hashimoto, Kim, & Adams, 2011). Fascin1 has emerged as an important biomarker and therapeutic target due to its overexpression in several carcinomas and its association with mortality and metastasis (Hashimoto et al., 2011; Hashimoto, Skacel, & Adams, 2005). In fact, several studies including a meta-analysis have demonstrated that Fascin1 expression is associated with increased lymph node- and distant-metastasis, disease progression and mortality in both colorectal and breast cancer (Omran & Al Sheeha, 2015; Tan, Lewis, Adams, & Martin, 2013).

In a recent study, our group identified Fascin1 as overexpressed in serrated adenocarcinoma (SAC) (Conesa-Zamora et al., 2013), a histological subtype of colorectal carcinoma. SAC, in contrast to conventional colorectal carcinoma (García-Solano, Conesa-Zamora, Trujillo-Santos, et al., 2012), has worse prognosis (García-Solano et al., 2010) and it is characterized by a more active invasive front evidenced by higher occurrence of tumor budding, cytoplasmic pseudofragments, infiltrative tumor growth pattern (García-Solano, Conesa-Zamora, Trujillo-Santos, Mäkinen, & Pérez-

Guillermo, 2011) and E-cadherin loss. Moreover, SACs show a higher frequency of KRAS and BRAF mutations than conventional carcinoma which make most of them resistant to anti-EGFR therapy (García-Solano, Conesa-Zamora, Carbonell, et al., 2012; Stefanius et al., 2011).

Given the causative role of Fascin1 in the invading phenotype of tumor cells together with the association of its overexpression to worse survival of a wide variety of cancer types (Cao et al., 2014; Jones et al., 2015; Li et al., 2014; Rodrigues et al., 2017; Stewart & Crook, 2015; Zhao et al., 2015) it would be desirable to find efficient Fascin1-activity blockers. In this line, migrastatin and its macroketone analogues are considered typical Fascin1 inhibitors (Chen et al., 2010). Unfortunately, they are difficult to synthesize due to their complex structure (Gaul et al., 2004).

In this study, we performed a search of patented potential Fascin1 inhibitors, such as those derived from indazol-furan-carboxamides (Han et al., 2016). Among them, we found the leading compound G2 and showed an inhibitory effect on Fascin1 activity by using several *in vitro* and *in vivo* assays on well-characterized colorectal cell lines.

Material and Methods

Compounds and molecular modeling

Compound G2 (N-(1-(4-(trifluoromethyl) benzyl)-1H-indazol-3-yl) furan-2-carboxamide; C₂₀H₁₅F₃N₃O₂; PM 386.13) is covered by the patents WO 2014/031732 A2 and WO 2015/127125A1 and was synthesized as previously described (Han et al., 2016). Migrastatin was synthesized by AnalytiCon Discovery (NP-006108) and provided by MolPort (Riga, Latvia). The geometry of compound G2 was built with

Autodock Tools (Morris et al., 2009), where partial charges were assigned using Gasteiger model (Gasteiger & Marsili, 1980). The structural model for Fascin1 was extracted from the crystal structure of protein data bank (PDB) with code 6B0T (Huang et al., 2018) and converted to PDBQT format using default parameters. Molecular docking calculations based on the Blind Docking (BD) technique (Sánchez-Linares, Pérez-Sánchez, Cecilia, & García, 2012) were carried out using Blind Docking server (BDS, available at <http://bio-hpc.ucam.edu/achilles>) with Autodock 4 (Morris et al., 2009) as docking engine with default parameters. Graphical representations of the docking results as PyMOL (<http://www.pymol.org>) sessions were downloaded from BDS with default options as specified on the website.

All the protocols comply with the recommendation, the approval of which was obtained from the participant institutions and in accordance to the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments.

Cell culture

Distinct human colorectal adenocarcinoma cell lines HCT-116, DLD-1, SW480, HCT-15, HT-29, LS174T, SW620 and LoVo were obtained from the American Type Culture Collection (ATCC, Rockville, MD, USA). Cell lines were cultivated using standard high glucose Dulbecco's Modified Eagle's Medium (DMEM) supplemented with 10% heat-inactivated fetal bovine serum (FBS), 50 U/mL penicillin and 50 µg/mL streptomycin (all from Sigma Aldrich Chemical Co., USA) at 37 °C and 5% CO₂ and 95% humidified atmosphere. Subculturing was performed when cells reached 90% confluence. Cell RNA extraction and qPCR for Fascin1 expression quantification is described in Supplementary Material S1. The human colorectal carcinoma cells were

genetically overexpressed (DLD-1) and knocked-down (HCT-116) for Fascin-1
(Supplementary Material S1).

Cell viability assay

Exponentially growing cells were plated in flat-bottomed 96-well plates (Nunc, Roskilde, Denmark) in triplicate (1500 cells/well). Cells were treated with a series of concentrations from 500 nM to 100 μ M of either migrastatin or compound G2 up to 3 days (24, 48 and 72 hours) in a 5% CO₂ humidified atmosphere. Control cells were treated with drug carrier [0.1% dimethyl sulfoxide (DMSO)]. Cells were assayed for viability as follows. Briefly, Dulbecco's phosphate-buffered saline (DPBS) supplemented with 1.9 mg/mL tetrazolium (MTT) pH 7.2 was added to the cells (30 μ L/well). After incubation at 37 °C for 4 hours, the medium was carefully aspirated. The formazan crystals were dissolved in 200 μ L DMSO for 30 min and the absorbance was read in a microtiter plate reader at 570 nm and 620 nm as reference. Results were calculated as: cell viability (%) = average optical density (O.D.) of wells/average O.D. of control wells.

Cell Migration Assay

Cell migration was studied using HCT-116 and DLD-1 cell lines by performing a scratch wound healing assay in standard medium supplemented with 5% FBS. Typically, 50,000 cells were plated in low 35-mm-dishes with culture inserts following manufacturer instructions (Ibidi, Martinsried, Germany). After appropriate cell attachment and monolayer formation (around 24 hours), inserts were removed with

sterile forceps to create a wound field of approximately 500 μm . Detached cells were gently removed with DPBS before the addition of drugs. Confluent cells were incubated in one of the following treatments: control (0.1% DMSO), 100 μM migrastatin, 5, 10 and 20 μM compound G2. Cells were then placed in a cell culture incubator and they were allowed to migrate. At 0, 4 and 7 hours (linear growth phase), 10 fields of the injury area were photographed with an inverted phase contrast microscope using 10X magnification. For each time point, the area uncovered by cells was determined by Image J software (National Institute of Health, Bethesda, MD, USA). Each treatment was performed in triplicate.

The migration speed of the wound closure was given as the percentage of the recovered area at each time point, relative to the initially covered area (t_0). The velocity of wound closure (%/h) was calculated according to the formula:

$$\text{Slope (\%/h)} = \frac{(\% \text{ covered area } t_x) - (\% \text{ covered area } t_o)}{(t_x - t_o)}$$

Slopes are expressed as percentages relative to control conditions.

Transwell invasion assay

The invasive capacity of HCT-116 cells was determined using Cytoselect TM 24 Well Cell Invasion Assay (Basement Membrane Colorimetric Format) with Matrigel[®] coated Transwell chambers (8 μm pore size) (Cell Biolabs Inc., CA, USA). Briefly, cells (9.5×10^4) were resuspended in serum-free medium with corresponding inhibitors (100 μM migrastatin and 20 μM compound G2) and seeded into the upper chamber. Additionally, 500 μL of standard medium were added to the well. After 30 hours of incubation, cells that remained on the upper chamber were scraped away with a cotton

1 swab, and the cells that had migrated through the matrigel and reached the bottom of the
2 chamber were stained with the cell stain solution provided in the kit. Invasiveness was
3
4 quantified by counting cells on the lower surface of the filter using Image J software
5
6 (National Institute of Health, Bethesda, MD, USA). In addition, invasive cells at the
7
8 bottom side of the filter were eluted and quantified at an absorbance of 560 nm.
9
10

11 12 13 14 15 16 *Myoma organotypic invasion model* 17

18
19 Tumoral cell invasion was assessed in the myoma organotypic cultures and performed
20 according to the previously published myoma model protocol (Nurmenniemi et al.,
21
22 2009; Åström, Heljasvaara, Nyberg, Al-Samadi, & Salo, 2018). Briefly, uterine
23
24 leiomyoma tissues were obtained from routine surgery after informed consent of the
25
26 donors and their use approved by The Ethics Committee of the Oulu University
27
28 Hospital. The myoma tissue was sliced into 5 mm and disks were made with an 8-mm
29
30 biopsy punch (Kai Industries Co., Gifu, Japan). Myoma disks were pre-incubated in
31
32 either 0.1% DMSO, 100 µM migrastatin, 10 µM and 20 µM compound G2 at 4 °C for
33
34 48 hours. The myoma disks were placed into Transwell inserts (diameter 6.5 mm;
35
36 Corning Incorporated, Corning, NY) and 700,000 cells in 50 µL of media were added
37
38 on top of each myoma disk. Cells were allowed to attach overnight and the myoma
39
40 disks, transferred onto uncoated nylon disks and be treated with the compounds for 14
41
42 days, while changing the treatment media every 3 days. Subsequently the myoma discs
43
44 were fixed with 4% neutral buffered formalin for 24 hours and 6 µm sections were cut
45
46 and stained with cytokeratin AE1/AE3 (M3515, Dako). Sections were documented at
47
48 10X magnifications, using the Leica DMRB microscope DFC 480 camera with the
49
50 Leica application suite v3.8 (Leica Microsystems, Wetzlar, Germany). Image J software
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

(National Institute of Health, Bethesda, MD, USA) was used to measure invasion areas and depths. Each treatment was performed in triplicate.

Zebrafish invasion assays and treatments

The colonization of zebrafish (ZF) (*Danio rerio*) embryos by human cancer colorectal cells lines was performed as previously described (Jelassi et al., 2011). The experiments performed comply with the Guidelines of the European Union Council (Directive 2010/63/EU) and the Spanish RD 53/2013. Experiments and procedures were performed as approved by the Bioethical Committee of the Murcia University (Spain). Briefly, human cell lines were trypsinized, washed and stained with fluorescent CM-Dil (Vibrant, Invitrogen) following manufacturer's instructions. Fifty to 100 labelled cells were injected into the yolk sac of dechorionated ZF embryos and transferred into 24 well plates. Fish with fluorescently labelled cells appearing outside the implantation area at 2 hours post-injection (dpi) were excluded from further analysis. All other fishes were treated, by bath immersion, with E3 medium (5 mM NaCl, 0.33 mM KCl, 0.33 mM CaCl₂, 0.33 mM MgSO₄, 0.1% methylene blue) (all from Sigma-Aldrich, St Louis, MO, USA) supplemented with either 100 µM migrastatin or 5-10 µM compound G2 for 96 hours at 35 °C. Treatment was renewed every 24 hours. Larvae analyzed with a M205-FA stereomicroscope equipped with a DFC365FX camera (Leica). The evaluation criteria for embryos being colonized by human cancer cells was the presence of more than three cells outside of the yolk sac and, with this criterion, ZF percentage of invasion was calculated.

With the aim of finding out whether the pro-metastatic activity of Fascin1-induced expression was affected by chemical compounds, a metastasis assay was carried out.

1 Zebrafish embryos xenografted with Fascin1-transfected DLD-1 cells were incubated
2 up to 144 hours. The day of invasion screening (fourth day post xenograft), freshly
3 prepared E3 medium was supplemented with 100 μ M migrastatin or 10 μ M compound
4 G2 together with 375 rotifers/mL (*Brachionus plicatilis* (L-type); ReefNutrition,
5 Campbell, CA, USA). The number of small colonies generated from individual
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

up to 144 hours. The day of invasion screening (fourth day post xenograft), freshly prepared E3 medium was supplemented with 100 μ M migrastatin or 10 μ M compound G2 together with 375 rotifers/mL (*Brachionus plicatilis* (L-type); ReefNutrition, Campbell, CA, USA). The number of small colonies generated from individual invading cells was counted on the sixth day post xenograft (6 dpi). This was considered as the number of ZF larvae with metastasis.

Data analysis

Data are expressed as mean $\pm$ standard deviation (SD). Data were analyzed for statistical differences by the Student's t-test for paired and unpaired data after testing for normal distribution of the data. For *in vitro* experiments, one-way analysis of variance (ANOVA) was performed followed by a Tukey poshoc test to compare each group. Differences were considered significant at an error probability of $P < 0.05$. SPSS 18.0 software was used for the rest of statistical analyses (SPSS, Inc, Chicago, Illinois, USA). For myoma assay OriginPro 2016 software was used for statistical calculations. One-way ANOVA (analysis of variance) with post-hoc comparisons based on the Tukey's multiple comparisons test were applied. The level of significance considered was 5% ($p \leq 0.05$).

Results

Molecular Modeling

Figure 1 shows the main resulting pose of compound G2 after blind docking calculations against whole Fascin1 protein surface. Most relevant intermolecular

1 interactions established are related to hydrogen bonds (GLU215), pi-pi (TRP101) and
2 hydrophobic interactions (LEU16, PHE14, LEU48, ILE93, VAL134, GLU215,
3 PHE216). It must be noticed that these residues participate in the actin-binding site 2,
4 located within the pocket formed by β -trefoil 1 and 2 from the Fascin1 structure, and
5 that blind docking calculations were able to predict this interaction spot with no
6 previous assumption about binding site. In addition, this prediction coincides rather well
7 with crystallographic pose of ligand compound G2-029 (PDB: 6B0T), which is to be
8 expected due to the small difference between compound G2 and G2-029 molecules, just
9 a methyl group.
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24

25 *Compound G2 prevents in vitro Fascin1-induced F-actin bundling*

26
27
28
29 In order to assess the effect of compound G2 on Fascin1, we performed an F-actin
30 bundling assay under transmission electron microscopy (TEM) (Supplementary material
31 S1). As shown in Figure 2, only F-actin incubated in the presence of untreated Fascin1
32 formed filament bundles (12.00 [9.00-19.75]). Fascin1 preincubated with 100 μ M
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100

101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200

201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300

301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400

401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500

501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600

601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700

701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
729
730
731
732
733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
765
766
767
768
769
770
771
772
773
774
775
776
777
778
779
780
781
782
783
784
785
786
787
788
789
790
791
792
793
794
795
796
797
798
799
800

801
802
803
804
805
806
807
808
809
810
811
812
813
814
815
816
817
818
819
820
821
822
823
824
825
826
827
828
829
830
831
832
833
834
835
836
837
838
839
840
841
842
843
844
845
846
847
848
849
850
851
852
853
854
855
856
857
858
859
860
861
862
863
864
865
866
867
868
869
870
871
872
873
874
875
876
877
878
879
880
881
882
883
884
885
886
887
888
889
890
891
892
893
894
895
896
897
898
899
900

901
902
903
904
905
906
907
908
909
910
911
912
913
914
915
916
917
918
919
920
921
922
923
924
925
926
927
928
929
930
931
932
933
934
935
936
937
938
939
940
941
942
943
944
945
946
947
948
949
950
951
952
953
954
955
956
957
958
959
960
961
962
963
964
965
966
967
968
969
970
971
972
973
974
975
976
977
978
979
980
981
982
983
984
985
986
987
988
989
990
991
992
993
994
995
996
997
998
999
1000

53 *Compound G2 affects cytoskeleton formation and Fascin1 localization at the*
54 *lamellipodium*
55
56
57
58
59
60
61
62
63
64
65

1 In order to choose colorectal cell lines with highest and lowest endogenous Fascin1
2 expression, a RT-qPCR was performed upon RNA extracted from eight cell lines. As
3
4 shown in **Supplementary Material 2**, HCT-116 and SW480 exhibited the highest
5
6 Fascin1 expression whilst LoVo, DLD-1 and HT-29 had the lowest. Given the ease for
7
8 cell culture and the differences in endogenous Fascin1 expression, we selected DLD-1
9
10 (low Fascin1 expression) and HCT-116 (high Fascin1 expression) cell lines in
11
12 subsequent assays.
13
14
15

16
17 To assess the Fascin1 inhibition activity of the compound G2 on cell viability, we tested
18
19 different concentration of migrastatin and compound G2 on different colorectal cancer
20
21 cells. As shown Supplementary Material S3, migrastatin was generally better tolerated
22
23 than compound G2 by the DLD-1 and HCT-116 cell lines. Thus, the working
24
25 concentrations for migrastatin and compound G2 were set up for subsequent *in vitro*
26
27 studies at 100 μ M and up to 20 μ M, respectively.
28
29
30
31

32
33 The effect of compound G2 on Fascin1 localization and the reorganization of the actin
34
35 cytoskeleton as well as on the protrusion of lamellipodium at the cell front was assessed
36
37 by immunofluorescence. For that purpose, we used HCT-116, the colorectal cell line
38
39 with maximum expression levels of Fascin1 **together with Fascin1 silenced HCT-116**
40
41 **cells.** As shown in Figure 3, prominent lamellipodium formation was observed in
42
43 control conditions and for EGF treated cells (non-significant differences between each
44
45 other were found). However, these cytoskeleton structures were absent in cells treated
46
47 with migrastatin and compound G2, similarly to what it was observed with PD98059, an
48
49 inhibitor targeting the MEK pathway. Lamellipodium protrusion numbers calculated at
50
51 different conditions were significantly lower upon both migrastatin and compound G2
52
53 treatments when compared to control conditions (Table 1). **Supplementary material S4**
54
55
56
57
58
59
60
61
62
63
64
65

showed that the treatments also abolished the actin bundles in lamellipodium. Similar results were observed with an extra cell line expressing Fascin1 (HaCat) as DLD1 morphology was not suitable for assessing lamellipodium formation (data not shown). Transcriptional Fascin1 silencing of HCT-116 abolished the Fascin1 accumulation at lamellipodium sites and produced an alteration of F-actin microfilament assembly in silenced cells (Supplemental S5D).

Compound G2 diminishes migration and inhibits Matrigel cell invasion of colorectal cancer cells

In order to correlate the observed effect of Fascin1 inhibitors on lamellipodium protrusion to an effect on cell migration, migrastatin and compound G2 treated cells were investigated for their migration activity using an *in vitro* wound healing scratch assay. As shown in Figure 4, compound G2 produces a remarkable inhibition of migration in HCT-116 and DLD-1 cell lines ($p < 0.01$). Compound G2 effect at 20 μ M was more pronounced than migrastatin in DLD-1 cells, whilst in HCT-116 the effect of compound G2 on migration was lower.

Tumor cell invasion not only involves the acquisition of migration properties but also the ability to degrade the basement membrane and tumor stoma matrices, three-dimensional substrates (Albini, 1998). For that reason, we performed a Transwell assay on Matrigel^R which resembles the basement membrane extracellular matrix composition. As shown in Supplementary material S6, both compound G2 and migrastatin inhibit tumor cell invasion of HCT-116, the effect of the latter being slightly more evident.

To further confirm the inhibitory effect of compound G2 on the Fascin1 activity, we used Fascin1 silenced HCT116 and fascin1 overexpressed DLD-1 cells and tested their

1 migration and invasion properties. Fascin1 silencing produces a slight decrease of
2 migration and invasion compared to MOCK HCT-116 cells ($p<0.05$), whereas double
3 inhibition (genetic and pharmacological) only produced a significant decrease in
4 migration (Supplemental material S7A-B). Accordingly, 10 μ M compound G2 strongly
5 diminished migration and invasion in Fascin1 overexpressed DLD-1 cells ($p<0.01$)
6 (Supplemental material S7C-D).

17 *Compound G2 diminishes HCT-116 colon cancer cells invasion in a human benign*
18 *leiomyoma tissue in vitro 3D model*

22 In order to find out whether the anti-invasive properties of compound G2 on cancer cell
23 invasion could be translated into a 3D human model, a myoma disc organotypic model
24 was used. As shown in Figure 5, compound G2 (5 μ M) significantly reduced the
25 invasion depth and invasion area of HCT-116 cells into the discs when compared to
26 untreated cells ($P<0.01$). Similar results were obtained when cells were treated with 10
27 and 20 μ M compound G2 (Supplementary material S8).

39 *Compound G2 inhibits the invasive capacity of HCT-116 tumor cells in an in vivo assay*
40 *of zebrafish model*

44 In order to find out whether the anti-invasive properties of compound G2 could be
45 extrapolated to a living animal, a xenograft assay was carried by using the well-
46 established zebrafish (ZF)-larvae invasion model. To test viability, groups of thirty
47 larvae were treated with either 100 μ M migrastatin or 5, 10 and 20 μ M compound G2.
48 The majority of larvae were viable after three days treatment with either 5 or 10 μ M.
49 However, 20 μ M compound G2 treatment caused larvae death at the third day of
50 treatment (Supplementary material S9A). Therefore, concentrations chosen for ZF

assays were 5 and 10 μ M compound G2. Later on, detached and labelled colorectal cancer cells were injected into the yolk sac and colonization was followed up to 6 days. The percentage of invasion was studied for four colorectal cancer cell lines (Fig. 6A and 6B) that exhibited different Fascin1 expression levels (Supplementary material S2). HCT-116 and DLD-1 were selected for being the cell lines with the highest and lower Fascin1 expression, respectively. Good correlation was observed between Fascin1 expression and cell invasion for all cell lines assayed except HCT-15 whose invasion was lower than expected (Figure 6B) possibly due to other fascin1 independent factors affecting invasion (Stevenson, Veltman, & Machesky, 2012). Therefore, and because of good correlation, HCT-116 was selected for being the cell line with the highest and DLD-1 for its lower Fascin1 expression and cell invasion. To further test the *in vivo* involvement of Fascin1 in this phenomenon, we performed exogenous silencing of Fascin1 in HCT-116 cells (Figure 7A). Either genetic reduction of Fascin1 or its pharmacological inhibition by compound G2 decreased the invasion in HCT-116 cells (Figures 7B and 7C). Conversely, we induced the over-expression of Fascin1 by means of plasmid transfection into DLD-1 cells (Figure 7D), thus correlating with a higher invasion capacity (Figure 7E). Compound G2 kept inhibiting invasion in both, MOCK and transfected Fascin1-overexpressing cells (Figure 7F). Consequently, *in vivo* invasion correlated with Fascin1 expression and compound G2 inhibited it in transfected cells (Figures 7E and 7F). Furthermore, a clear increase of the number of ZF larvae with metastasis was observed with Fascin1-overexpressing DLD-1 cells although 10 μ M compound G2 treatment had a similar effect on ZF groups subjected to either Fascin1 transfected or wild-type DLD-1 cells (Supplementary material S10).

Discussion

Colorectal serrated adenocarcinoma and triple negative breast carcinoma are characterized by their bad prognosis, over-expression of Fascin1 and the absence of targeted molecular therapy (Conesa-Zamora et al., 2013; Esnakula et al., 2014; García-Solano, Conesa-Zamora, Carbonell, et al., 2012; García-Solano et al., 2016; Ghebeh et al., 2014; Kanda et al., 2014; Rodríguez-Pinilla et al., 2006; Stefanius et al., 2011; Wang et al., 2016). Han *et al.* demonstrated an inhibitory effect of compound G2 and its derivatives on Fascin1-driven actin bundling. Moreover, they showed an anti-migratory and anti-invasive effect of compound G2 on breast cancer cells (Han et al., 2016). In the present report we include a molecular model, which provided an improved understanding regarding atomic details of the interactions between compound G2 chemical class and Fascin1 inhibition and will guide the future identification of more potent anti-metastatic drugs. Using blind docking calculations, the model identified a region in Fascin1 possibly involved in compound G2 binding. Some prior evidences support this finding as this region is part of the actin binding site 1, as described by Han *et al.* (Han et al., 2016). In accordance, preincubation of Fascin1 with migrastatin and compound G2 disrupted the F-actin bundle formation *in vitro*. Herein, among the different colorectal cell lines used in this study, HCT-116 expressed the highest Fascin1 levels and its migration capacity was clearly reduced after treatment with compound G2, even at lower concentrations than migrastatin and in a dose-dependent manner. Invasion and confocal studies were further performed with HCT-116 cells because of its morphological features and higher Fascin1 expression levels. We showed that both inhibitors, migrastatin and compound G2, strongly abolished the protrusion of lamellipodium, as confirmed by rescue experiments in Fascin1 silenced cells. Furthermore, we observed similar inhibitory effects of migrastatin and compound G2 on the Matrigel invasion assays with naïve and transfected HCT-116 and DLD-1 cells.

1 Myoma discs represent a superior 3D model for cancer cell invasion studies compared
2 to the other, non-human tissue based, organotypic models (Salo et al., 2018). In myoma
3 assay, both migrastatin and compound G2 were similarly able to significantly decrease
4 both the invasion depth and invasion area of HCT-116 cells. It is important to notice
5 that cell death caused by long-time incubation with the compound G2 was avoided in
6 the migration and invasion *in vitro* assays, since viability did not seem to be
7 compromised after 30 hours. Of note, no previous studies have analyzed the effect of
8 migrastatin or compound G2 on human solid, hypoxic, myoma disc organotypic
9 invasion assay.

10 Moreover, *in vivo* assays using a model of ZF where Fascin1 expression was modified
11 in colorectal cells showed that compound G2 effects on colorectal cancer cells invasion
12 capacities showed a Fascin1 dependency. This compound inhibits the invasion of two
13 cell lines of colorectal cancer with high expression of Fascin1, both constitutive and
14 induced, without affecting the ZF viability and with a more pronounced effect than
15 migrastatin. This activity also had an effect on colony formation from individual
16 invading cells thus suggesting an inhibition of both invasion and metastasis of Fascin1-
17 transfected tumor cells. It is worth of mentioning that this validated model was capable
18 of testing a very high number of individuals per assay. However and despite these
19 evidences, additional off-target anti-tumoral effects of G2 apart from Fascin1 are also
20 possible.

21 In conclusion, this study reports a Fascin1 inhibitor with anti-migratory and anti-
22 invasive properties in colorectal cancer cells at lower concentrations than migrastatin,
23 the typical Fascin1 inhibitor. Using this strategy, we have here confirmed a novel class
24 of compounds for the study of therapeutic approaches for invasive and metastatic

tumoral cells, such as SAC; providing the first rationale for a tailored therapy in this type of cancer.

REFERENCES

- Albini, A. (1998). Tumor and endothelial cell invasion of basement membranes. The matrigel chemoinvasion assay as a tool for dissecting molecular mechanisms. *Pathol Oncol Res*, 4(3), 230-241. doi:10.1007/bf02905254
- Cao, H. H., Zheng, C. P., Wang, S. H., Wu, J. Y., Shen, J. H., Xu, X. E., . . . Xu, L. Y. (2014). A molecular prognostic model predicts esophageal squamous cell carcinoma prognosis. *PLoS One*, 9(8), e106007. doi:10.1371/journal.pone.0106007
- Chen, L., Yang, S., Jakoncic, J., Zhang, J. J., & Huang, X. Y. (2010). Migrastatin analogues target fascin to block tumour metastasis. *Nature*, 464(7291), 1062-1066. doi:10.1038/nature08978
- Conesa-Zamora, P., García-Solano, J., García-García, F., Turpin, M. e. C., Trujillo-Santos, J., Torres-Moreno, D., . . . Pérez-Guillermo, M. (2013). Expression profiling shows differential molecular pathways and provides potential new diagnostic biomarkers for colorectal serrated adenocarcinoma. *Int J Cancer*, 132(2), 297-307. doi:10.1002/ijc.27674
- Esnakula, A. K., Ricks-Santi, L., Kwagyan, J., Kanaan, Y. M., DeWitty, R. L., Wilson, L. L., . . . Naab, T. J. (2014). Strong association of fascin expression with triple negative breast cancer and basal-like phenotype in African-American women. *J Clin Pathol*, 67(2), 153-160. doi:10.1136/jclinpath-2013-201698
- García-Solano, J., Conesa-Zamora, P., Carbonell, P., Trujillo-Santos, J., Torres-Moreno D, D., Pagán-Gómez, I., . . . Pérez-Guillermo, M. (2012). Colorectal serrated adenocarcinoma shows a different profile of oncogene mutations, MSI status and DNA repair protein expression compared to conventional and sporadic MSI-H carcinomas. *Int J Cancer*, 131(8), 1790-1799. doi:10.1002/ijc.27454
- García-Solano, J., Conesa-Zamora, P., Trujillo-Santos, J., Mäkinen, M. J., & Pérez-Guillermo, M. (2011). Tumour budding and other prognostic pathological features at invasive margins in serrated colorectal adenocarcinoma: a comparative study with conventional carcinoma. *Histopathology*, 59(6), 1046-1056. doi:10.1111/j.1365-2559.2011.04043.x
- García-Solano, J., Conesa-Zamora, P., Trujillo-Santos, J., Torres-Moreno, D., Mäkinen, M. J., & Pérez-Guillermo, M. (2012). Immunohistochemical expression profile of β -catenin, E-cadherin, P-cadherin, laminin-5 γ 2 chain, and SMAD4 in colorectal serrated adenocarcinoma. *Hum Pathol*, 43(7), 1094-1102. doi:10.1016/j.humpath.2011.08.020
- García-Solano, J., García-Solano, M. E., Torres-Moreno, D., Carbonell, P., Trujillo-Santos, J., Pérez-Guillermo, M., & Conesa-Zamora, P. (2016). Biomarkers for the identification of precursor polyps of colorectal serrated adenocarcinomas. *Cell Oncol (Dordr)*, 39(3), 243-252. doi:10.1007/s13402-016-0269-5
- García-Solano, J., Pérez-Guillermo, M., Conesa-Zamora, P., Acosta-Ortega, J., Trujillo-Santos, J., Cerezuela-Fuentes, P., & Mäkinen, M. J. (2010). Clinicopathologic study of 85 colorectal serrated adenocarcinomas: further insights into the full recognition of a new subset of colorectal carcinoma. *Hum Pathol*, 41(10), 1359-1368. doi:10.1016/j.humpath.2010.04.002
- Gasteiger, J., & Marsili, M. (1980). Iterative partial equalization of orbital electronegativity—a rapid access to atomic charges Y1 - 1980 Y2 - 1980. *Tetrahedron*, 36(22), 3219-3228. doi:[https://doi.org/10.1016/0040-4020\(80\)80168-2](https://doi.org/10.1016/0040-4020(80)80168-2) M1 - Generic

- Gaul, C., Njardarson, J. T., Shan, D., Dorn, D. C., Wu, K. D., Tong, W. P., . . . Danishefsky, S. J. (2004). The migrastatin family: discovery of potent cell migration inhibitors by chemical synthesis. *J Am Chem Soc*, 126(36), 11326-11337. doi:10.1021/ja048779q
- Ghebeh, H., Al-Khaldi, S., Olabi, S., Al-Dhfyhan, A., Al-Mohanna, F., Barnawi, R., . . . Al-Alwan, M. (2014). Fascin is involved in the chemotherapeutic resistance of breast cancer cells predominantly via the PI3K/Akt pathway. *Br J Cancer*, 111(8), 1552-1561. doi:10.1038/bjc.2014.453
- Han, S., Huang, J., Liu, B., Xing, B., Bordeleau, F., Reinhart-King, C. A., . . . Huang, X. Y. (2016). Improving fascin inhibitors to block tumor cell migration and metastasis. *Mol Oncol*, 10(7), 966-980. doi:10.1016/j.molonc.2016.03.006
- Hashimoto, Y., Kim, D. J., & Adams, J. C. (2011). The roles of fascins in health and disease. *J Pathol*, 224(3), 289-300. doi:10.1002/path.2894
- Hashimoto, Y., Skacel, M., & Adams, J. C. (2005). Roles of fascin in human carcinoma motility and signaling: prospects for a novel biomarker? *Int J Biochem Cell Biol*, 37(9), 1787-1804. doi:10.1016/j.biocel.2005.05.004
- Huang, J., Dey, R., Wang, Y., Jakoncic, J., Kurinov, I., & Huang, X. Y. (2018). Structural Insights into the Induced-fit Inhibition of Fascin by a Small-Molecule Inhibitor. *J Mol Biol*, 430(9), 1324-1335. doi:10.1016/j.jmb.2018.03.009
- Jelassi, B., Chantôme, A., Alcaraz-Pérez, F., Baroja-Mazo, A., Cayuela, M. L., Pelegrin, P., . . . Roger, S. (2011). P2X(7) receptor activation enhances SK3 channels- and cystein cathepsin-dependent cancer cells invasiveness. *Oncogene*, 30(18), 2108-2122. doi:10.1038/onc.2010.593
- Jones, R. P., Bird, N. T., Smith, R. A., Palmer, D. H., Fenwick, S. W., Poston, G. J., & Malik, H. Z. (2015). Prognostic molecular markers in resected extrahepatic biliary tract cancers; a systematic review and meta-analysis of immunohistochemically detected biomarkers. *Biomark Med*, 9(8), 763-775. doi:10.2217/BMM.15.48
- Kanda, Y., Kawaguchi, T., Kuramitsu, Y., Kitagawa, T., Kobayashi, T., Takahashi, N., . . . Okada, F. (2014). Fascin regulates chronic inflammation-related human colon carcinogenesis by inhibiting cell anoikis. *Proteomics*, 14(9), 1031-1041. doi:10.1002/pmic.201300414
- Li, A., Morton, J. P., Ma, Y., Karim, S. A., Zhou, Y., Faller, W. J., . . . Machesky, L. M. (2014). Fascin is regulated by slug, promotes progression of pancreatic cancer in mice, and is associated with patient outcomes. *Gastroenterology*, 146(5), 1386-1396.e1381-1317. doi:10.1053/j.gastro.2014.01.046
- Machesky, L. M., & Li, A. (2010). Fascin: Invasive filopodia promoting metastasis. *Commun Integr Biol*, 3(3), 263-270. doi:10.4161/cib.3.3.11556
- Morris, G. M., Huey, R., Lindstrom, W., Sanner, M. F., Belew, R. K., Goodsell, D. S., & Olson, A. J. (2009). AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility. *J Comput Chem*, 30(16), 2785-2791. doi:10.1002/jcc.21256
- Nurmenniemi, S., Sinikumpu, T., Alahuhta, I., Salo, S., Sutinen, M., Santala, M., . . . Salo, T. (2009). A novel organotypic model mimics the tumor microenvironment. *Am J Pathol*, 175(3), 1281-1291. doi:10.2353/ajpath.2009.081110
- Omran, O. M., & Al Sheeha, M. (2015). Cytoskeletal Focal Adhesion Proteins Fascin-1 and Paxillin Are Predictors of Malignant Progression and Poor Prognosis in Human Breast Cancer. *J Environ Pathol Toxicol Oncol*, 34(3), 201-212.
- Rodrigues, P. C., Sawazaki-Calone, I., Ervolino de Oliveira, C., Soares Macedo, C. C., Dourado, M. R., Cervigne, N. K., . . . Coletta, R. D. (2017). Fascin promotes migration and invasion and is a prognostic marker for oral squamous cell carcinoma. *Oncotarget*, 8(43), 74736-74754. doi:10.18632/oncotarget.20360
- Rodríguez-Pinilla, S. M., Sarrió, D., Honrado, E., Hardisson, D., Calero, F., Benitez, J., & Palacios, J. (2006). Prognostic significance of basal-like phenotype and fascin expression in node-negative invasive breast carcinomas. *Clin Cancer Res*, 12(5), 1533-1539. doi:10.1158/1078-0432.CCR-05-2281

- 1 Salo, T., Dourado, M. R., Sundquist, E., Apu, E. H., Alahuhta, I., Tuomainen, K., . . . Al-Samadi, A.
2 (2018). Organotypic three-dimensional assays based on human leiomyoma-derived
3 matrices. *Philos Trans R Soc Lond B Biol Sci*, 373(1737). doi:10.1098/rstb.2016.0482
- 4 Stefanius, K., Ylitalo, L., Tuomisto, A., Kuivila, R., Kantola, T., Sirniö, P., . . . Mäkinen, M. J.
5 (2011). Frequent mutations of KRAS in addition to BRAF in colorectal serrated
6 adenocarcinoma. *Histopathology*, 58(5), 679-692. doi:10.1111/j.1365-
7 2559.2011.03821.x
- 8 Stevenson, R. P., Veltman, D., & Machesky, L. M. (2012). Actin-bundling proteins in cancer
9 progression at a glance. *J Cell Sci*, 125(Pt 5), 1073-1079. doi:10.1242/jcs.093799
- 10 Stewart, C. J., & Crook, M. L. (2015). Fascin expression in undifferentiated and dedifferentiated
11 endometrial carcinoma. *Hum Pathol*, 46(10), 1514-1520.
12 doi:10.1016/j.humpath.2015.06.011
- 13 Sánchez-Linares, I., Pérez-Sánchez, H., Cecilia, J. M., & García, J. M. (2012). High-Throughput
14 parallel blind Virtual Screening using BINDSURF. *BMC Bioinformatics*, 13 Suppl 14, S13.
15 doi:10.1186/1471-2105-13-S14-S13
- 16 Tan, V. Y., Lewis, S. J., Adams, J. C., & Martin, R. M. (2013). Association of fascin-1 with
17 mortality, disease progression and metastasis in carcinomas: a systematic review and
18 meta-analysis. *BMC Med*, 11, 52. doi:10.1186/1741-7015-11-52
- 19 Wang, C. Q., Tang, C. H., Chang, H. T., Li, X. N., Zhao, Y. M., Su, C. M., . . . Huang, B. F. (2016).
20 Fascin-1 as a novel diagnostic marker of triple-negative breast cancer. *Cancer Med*,
21 5(8), 1983-1988. doi:10.1002/cam4.746
- 22 Zhao, W., Gao, J., Wu, J., Liu, Q. H., Wang, Z. G., Li, H. L., & Xing, L. H. (2015). Expression of
23 Fascin-1 on human lung cancer and paracarcinoma tissue and its relation to
24 clinicopathological characteristics in patients with lung cancer. *Onco Targets Ther*, 8,
25 2571-2576. doi:10.2147/OTT.S81915
- 26 Åström, P., Heljasvaara, R., Nyberg, P., Al-Samadi, A., & Salo, T. (2018). Human Tumor Tissue-
27 Based 3D In Vitro Invasion Assays. *Methods Mol Biol*, 1731, 213-221. doi:10.1007/978-
28 1-4939-7595-2_19

Table 1. Lamellipodium protrusion numbers in the different conditions in HCT-116 cells.

	Control	100 µM	20 µM	10 ng/mL	50 µM
		migrastatin	compound G2	EGF	PD98059
Lamellipodium numbers	9 ± 1.5	2 ± 2	5.8 ± 1.1	10.4 ± 1.5	1 ± 1
P value*		0,000139	0,002936	0,140178	5,9241E⁻⁰⁶

* T-student test compared to control condition.

Figure legends

Figure 1. Main interactions obtained after blind docking of compound G2 against Fascin1. Blue solid line represents hydrogen bond, green dashed line aromatic interactions, and dashed grey lines hydrophobic interactions. Inset: compound G2 chemical structure.

Figure 2. Transmission electronic microscopy visualization of actin binding and bundling activities of Fascin1 treated or not with inhibitors (negative staining). A) Stained F-actin filaments alone. B) F-actin bundling assay with filamentous F-actin and untreated Fascin1 (1:1 molecular ratio) (control condition). C) F-actin bundling assay with filamentous F-actin and Fascin1 previously incubated with 100 μ M migrastatin (1:1 molecular ratio). D) F-actin bundling assay with filamentous F-actin and Fascin1 previously incubated with 20 μ M compound G2. Magnification: A 120.000X and B to D 93.000X. E) Quantitative analysis of the numbers of actin filaments bundles in the stated conditions (*** $p < 0.001$ compared to control condition), non-significant (N.S.) between treatments (Kruskal-Wallis test).

Figure 3. Migrastatin and compound G2 affect lamellipodium formation and morphology of HCT-116. Representative images of immunofluorescence assays for Fascin1 (lower inset in detail) are shown. A) Control condition; B) 100 μ M migrastatin; C) 20 μ M compound G2; D) 50 μ M PD98059 (Mek inhibitor); E) 10 ng/mL Epidermal Growth Factor (EGF, migration stimulator). Cells were fixed and stained with anti-Fascin1 antibody (1/250). Images were captured with a LSM 510 META confocal fluorescence microscope with 63X oil objective. Fascin1 location is show in green in these structures. Co-staining with Hoechst-33258 was used to show the cell nuclei. Both

migrastatin and compound G2 inhibited lamellipodium protrusion and Fascin1 localization in a similar way to the migration Mek inhibitor.

Figure 4. Migrastatin and compound G2 prevent cell migration on HCT-116 and DLD-1 colorectal cancer cells. A) Effect of 100 μ M migrastatin and 20 μ M compound G2 on HCT-116 and B) DLD-1 cells. C) Percentage of migration for 100 μ M migrastatin and compound G2 (5, 10, 20 μ M) treatments. Migration was calculated with respect to the control conditions (100%) for a slope between 4 and 7 hours (lineal phase). ** $p < 0.01$.

Figure 5. Myoma organotypic invasion model in HCT-116 cell line. A) Invasion of the cells within myoma discs after treatment in control conditions, B) 100 μ M migrastatin, and C) 5 μ M compound G2. Pictures were taken under a phase contrast microscope with 100X magnification and 100 μ m scale bars. D) The invasion area and E) Invasion depth of cytokeratin positive cells were quantified with image J. Data is shown as mean $\pm$ SD compared with the control. *** $p < 0.001$.

Figure 6. Zebrafish invasion assays. A) Zebrafish invasion model. Representative images of a zebrafish embryo with no invasion where the labeled cells remained in the yolk and never invaded the embryo and an embryo with invasion where the cells were able to migrate outside of the yolk. Magnification of the tail region of an embryo with invasion is shown at the right. B) Invasiveness of each cell line in this model. Data is shown as mean $\pm$ SD; compared with the control. * $p = 0.049-0.01$; ** $p = 0.001-0.009$.

Figure 7. Treatment effects on cancer cell invasion with different grades of Fascin1 expression. A) Inhibition of Fascin1 gene expression upon siRNA-Fascin1 transfection in HCT-116 cells. B) Effect of 5 and 10 μ M compound G2 on HCT-116 invasion with endogenous and silenced Fascin1 expression. C) Compound G2 inhibitory activity on control and siRNA Fascin1-transfected HCT-116 cells. First two columns represent the

1 difference between percentage of invasion in control (MOCK) and percentage of
2 invasion in treated cells. Second two columns represent the difference between
3 percentage of invasion in siRNA Fascin1-transfected HCT-116 and percentage of
4 invasion in compound G2-treated siRNA Fascin1-transfected HCT-116 cells. Note that
5 the effect of compound G2 decreased when Fascin1 was silenced. D) Overexpression of
6 Fascin1 gene upon Fascin1 transfection in DLD-1. E) Effect of 5 and 10 μ M compound
7 G2 on DLD-1 invasion with endogenous and exogenous Fascin1 expression. F)
8 Compound G2 inhibitory activity on control and Fascin1-transfected DLD-1 cells. First
9 two columns represent the difference between percentage of invasion in control
10 (MOCK) and percentage of invasion in treated cells. Second two columns represent the
11 difference between percentage of invasion in Fascin1-transfected DLD-1 and
12 percentage of invasion in compound G2-treated Fascin1-transfected DLD-1. Note that
13 the effect of compound G2 increased when Fascin1 was overexpressed by transfection.
14 Data is shown as mean $\pm$ SD; compared with the control, *p= 0,049-0, 01. ** p=0,001-
15 0,009. *** p= 0, 0001-0, 0009. **** p<0, 0001.

Supplementary material

Supplementary material S1. Detailed description of experimental protocols.

Supplementary material S2. Fascin1 gene expression in colorectal cell lines. mRNA expression levels of Fascin1 was quantified in eight colorectal cell lines using a β -actin gene expression for data normalizing.

Supplemental material S3. Colorectal cell line viability assay. The effect of migrastatin and compound G2 concentrations in HCT-116 and DLD-1 cell lines is shown. A-B) 24 hours; C-D) 48 hours; E-F) 72 hours incubation.

Supplementary material S4. Representative images of immunofluorescence assays for actin are shown in HCT-116 cells. A) Control condition; B) 100 μ M migrastatin; C) 20 μ M compound G2; D) 50 μ M PD98059 (Mek inhibitor); E) 10 ng/mL Epidermal Growth Factor (EGF, migration stimulator). For actin staining, cells were fixed and stained with anti-actin antibody (1/1000). Images were captured with a LSM 510 META confocal fluorescence microscope with 63X oil objective. Actin filaments are shown in red in these structures. Co-staining with Hoechst-33258 was used to show the cell nuclei. Lamellipodium are more prominent in control and EGF conditions.

Supplementary material S5. Representative images of immunofluorescence assays for fascin1 (green), nucleus (blue) and actin (red) are shown. A) Control condition (DMSO) with siRNA-A transfected HCT-116 cells; B) Control condition (DMSO) with fascin1 silenced HCT-116 cells; C) Fascin1 silenced HCT-116 cells with 10 ng/mL Epidermal Growth Factor (EGF, migration stimulator), D) Fascin1 silenced HCT-116 cells with 50 μ M PD98059 (Mek inhibitor). Colorectal carcinoma HCT-116 cells were genetically knocked-down for Fascin1 with short interfering siRNA, control HCT-116 was transfected with siRNA-A (MOCK). Cells were fixed with bouin and co-stained with anti-Fascin1 antibody (1/250) and Hoechst-33258. For actin staining, cells were fixed with methanol and stained with anti-actin antibody (1/1000). Images were captured with a LSM 510 META confocal fluorescence microscope with 63X oil objective.

Supplementary material S6. Transwell invasion assay in HCT-116 cell line. A) Invasiveness of cells after treatment in control conditions, 100 μ M migrastatin and 20 μ M compound G2, respectively. Pictures were taken under an inverted phase contrast microscope. The magnification was 200X and scale bars =50 μ m. B) Quantification of the invasive cells D.O. by a spectrophotometer at λ =560 nm. C) Number of invasive

cells using the Image J software. Data is shown as mean $\pm$ SD; compared with the control. **p<0.01.

Supplementary material S7. Inhibition of the migration and invasive capacities by compound G2 in transfected cells. A) Percentage of migration. B) Percentage of invasion. Colorectal carcinoma HCT-116 cells were genetically knocked-down for Fascin1 with short interfering siRNA, MOCK control HCT-116 was transfected with siRNA-A. Colorectal carcinoma DLD-1 cells were genetically overexpressed for Fascin1 with Fascin1-GFP vector, MOCK control DLD-1 was transfected with pGFP N3 control vector. Data are representative of two similar experiments Error bars, mean $\pm$ SD of duplicates. * p<0.05, ** p<0.01 compared to MOCK condition; n.s: non-significant.

Supplementary material S8. Myoma organotypic invasion model in HCT-116 cell line. A) Invasion of the cells within myoma discs after treatment in A) control conditions; B) 100 μ M migrastatin; C) 20 compound G2 and D) 10 μ M compound G2. Pictures were taken under a phase contrast microscope with 100X magnification and 100 μ m scale bars. E) Invasion area and F) Invasion depth of cytokeratin positive cells were quantified with image J. Data is shown as mean $\pm$ SD compared with the control. ** p<0.01 ***p<0.001.

Supplementary material S9. Viability of treated zebrafish larvae in the E3 medium. A) Non injected larvae. B) Additionally, larvae (>20 per condition) were injected with HCT-116 and treatments were added to the E3 medium. C) Larvae were injected with transfected DLD-1 tumoral cell lines and treated.

Supplementary material S10. Metastasis potential. The number of colonies generated was counted at 6 dpi. A) Individual invading DLD-1 cells. B) Both groups of non-

transfected and Fascin1-transfected DLD-1 cells showed a decrease in the number of
larvae with metastasis.

Figure 1

[Click here to access/download;Figure;Figure 1.tif](#)

Figure 5

[Click here to access/download;Figure;Figure 5.tif](#)

Figure 7

[Click here to access/download;Figure;figure 7.tif](#)

[Click here to access/download](#)

Supplementary Material

Montoro_et_al-Supplementary material R2.docx